SARS-CoV-2 mRNA vaccine induced higher antibody affinity and IgG titers against variants of concern in post-partum vs non-post-partum women.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Lee, YouriGrubbs, Gabrielle
Ramelli, Sabrina C
Levine, Andrea R
Bathula, Allison
Saharia, Kapil
Purcell, Madeleine
Singireddy, Shreya
Dugan, Colleen L
Kirchoff, Lindsey
Lankford, Allison
Cipriano, Sarah
Curto, Ryan A
Wu, Jocelyn
Raja, Katherine
Kelley, Emily
Herr, Daniel
Vannella, Kevin M
Ravichandran, Supriya
Tang, Juanjie
Harris, Anthony
Sajadi, Mohammad
Chertow, Daniel S
Grazioli, Alison
Khurana, Surender
Date
2022-03-14Journal
EBioMedicinePublisher
ElsevierType
Article
Metadata
Show full item recordAbstract
Background: Limited knowledge exists in post-partum women regarding durability of SARS-CoV-2 vaccine-induced antibody responses and their neutralising ability against SARS-CoV-2 variants of concern (VOC). Methods: We elucidated longitudinal mRNA vaccination-induced antibody profiles of 13 post-partum and 13 non-post-partum women (control). Findings: The antibody neutralisation titres against SARS-CoV-2 WA-1 strain were comparable between post-partum and non-post-partum women and these levels were sustained up to four months post-second vaccination in both groups. However, neutralisation titers declined against several VOCs, including Beta and Delta. Higher antibody binding was observed against SARS-CoV-2 receptor-binding domain (RBD) mutants with key VOC amino acids when tested with post-second vaccination plasma from post-partum women compared with controls. Importantly, post-vaccination plasma antibody affinity against VOCs RBDs was significantly higher in post-partum women compared with controls. Interpretation: This study demonstrates that there is a differential vaccination-induced immune responses in post-partum women compared with non-post-partum women, which could help inform future vaccination strategies for these groups.Rights/Terms
Published by Elsevier B.V.Identifier to cite or link to this item
http://hdl.handle.net/10713/18315ae974a485f413a2113503eed53cd6c53
10.1016/j.ebiom.2022.103940
Scopus Count
Related articles
- Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex.
- Authors: Tang J, Grubbs G, Lee Y, Huang C, Ravichandran S, Forgacs D, Golding H, Ross TM, Khurana S
- Issue date: 2021 Dec
- Humoral immune response after different SARS-CoV-2 vaccination regimens.
- Authors: Rose R, Neumann F, Grobe O, Lorentz T, Fickenscher H, Krumbholz A
- Issue date: 2022 Jan 21
- AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.
- Authors: Chibwana MG, Moyo-Gwete T, Kwatra G, Mandolo J, Hermanaus T, Motlou T, Mzindle N, Ayres F, Chaponda M, Tembo G, Mwenechanya P, Mitole N, Jassi C, Kamng'ona R, Afran L, Mzinza D, Mwandumba HC, Gordon SB, Jere K, Madhi S, Moore PL, Heyderman RS, Jambo KC
- Issue date: 2022 Mar 28
- High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
- Authors: Nitahara Y, Nakagama Y, Kaku N, Candray K, Michimuko Y, Tshibangu-Kabamba E, Kaneko A, Yamamoto H, Mizobata Y, Kakeya H, Yasugi M, Kido Y
- Issue date: 2021 Dec 22
- The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
- Authors: Tejedor Vaquero S, de Campos-Mata L, Ramada JM, Díaz P, Navarro-Barriuso J, Ribas-Llaurado C, Rodrigo Melero N, Carolis C, Cerutti A, Gimeno R, Magri G
- Issue date: 2021